RYTM Q1 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+25.9% YoY

Gross Profit

$29M88.8% margin

Operating Income

-$47M-143.7% margin

Net Income

-$49M-151.4% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

-21.8%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$387M

Total Liabilities

$224M

Stockholders' Equity

$163M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$26M	+25.9%
Gross Profit	$29M	$23M	+25.5%
Operating Income	-$47M	-$140M	+66.4%
Net Income	-$49M	-$141M	+65.0%

Revenue Segments

Product

$38M100%

Geographic Segments

Non-US

$13M100%